GLP-1 drugs reveal shared neurobiological roots of obesity and addiction, exposing systemic gaps in mental health care
Original framing: “Weight-loss drugs like Ozempic could work for addiction too – and we finally know how” — The Conversation - Global
GLP-1 drugs (e.g., semaglutide) modulate dopamine pathways and gut-brain signaling, offering evidence that obesity and addiction share neurobiological mechanisms. However, the research often prioritizes short-term efficacy over long-term outcomes, with limited studies on populations outside wealthy nations. The focus on GLP-1 obscures the role of endocrine disruptors (e.g., BPA, PFAS) in disrupting reward systems, which are rarely addressed in clinical trials.
The GLP-1 narrative exemplifies how biomedical reductionism obscures the shared roots of obesity and addiction in late-stage capitalism, where corporations profit from both the disease (ultra-processed foods, environmental toxins) and the cure (patented drugs).
Indigenous traditions and Global South healing practices offer holistic frameworks that treat addiction as a communal wound, yet these are sidelined in favor of a Western model that medicalizes behavior while ignoring structural violence. The scientific breakthrough in GLP-1’s mechanism is real, but its framing as a 'miracle drug' serves as a distraction from the need for systemic reforms—from food industry regulation to universal healthcare. The trickster’s irony lies in how this narrative both exposes and conceals: it reveals the neurobiological links between obesity and addiction while hiding the corporate and colonial systems that manufacture these crises. True solutions require dismantling these systems, not just tweaking brain chemistry.